PR91262

MELBOURNE, Australia, Aug. 23, 2021 /PRNewswire=KYODO JBN/ --

Melbourne biotech company Starpharma has announced the publication of new data

demonstrating the capability of its Viraleze antiviral nasal spray to protect

against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1].

Viraleze administered nasally reduced viral load by more than 99.9% in the

lungs and trachea of animals challenged with the SARS-CoV-2 virus, compared to

saline-control.

The findings, published in the peer-reviewed journal Viruses, in a special

issue titled Medical Interventions for Treatment and Prevention of SARS-CoV-2

Infections (https://www.mdpi.com/1999-4915/13/8/1656), provides further

validation for Viraleze against SARS-CoV-2.

The antiviral agent in Viraleze, SPL7013, has previously been shown in vitro to

have potent antiviral and virucidal activity in multiple variants of

SARS-CoV-2, including inactivation of >99.9% of the Delta variant

(https://starpharma.com/news/).

Viraleze was developed for application in the nasal cavity to help reduce

exposure to respiratory viruses, including SARS-CoV-2. The product is

registered for sale in Europe and India, and available online in certain

markets via www.viraleze.co.

Global data indicates that vaccines against COVID-19 are highly effective in

preventing hospitalisation and death, but that vaccinated individuals can still

become infected and shed virus. Complementary interventions, like Viraleze,

could potentially be used to reduce viral load at the primary site of initial

infection and could also be helpful to reduce shedding of infectious virus.

The latest study, conducted at The Scripps Research Institute, used a humanised

SARS-CoV-2 mouse model recommended by the WHO. The results show that Viraleze

administered nasally significantly reduced SARS-CoV-2 viral load in the

respiratory tract, in the blood and in other organs in Viraleze treated

animals.

The impressive protective effects of Viraleze in this SARS-CoV-2 animal model

are consistent with the previously reported virucidal activity of SPL7013[2],

demonstrating potent antiviral activity in multiple respiratory viruses and

multiple variants of SARS-CoV-2.

Starpharma CEO, Dr Jackie Fairley, said: "In this study Viraleze was highly

protective against SARS-CoV-2 challenge in an established SARS-CoV-2 animal

model of coronavirus infection. These results provide compelling data

supporting the utility of a broad-spectrum nasal spray, like Viraleze, to

potentially reduce exposure to SARS-CoV-2 virus in respiratory tract and other

organs. One of the potential advantages of Viraleze is its ability to

significantly reduce viral load in the respiratory tract, which could lower

both the transmissibility of the virus to others and severity of disease."

[1] The study used the K18-hACE2 mouse model, an in vivo humanised mouse model

that expresses the human angiotensin converting enzyme (hACE2) receptor, the

receptor used by SARS-CoV-2 to infect cells in the human nasal cavity and

respiratory tract.

[2] Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium

against SARS-CoV-2 in vitro (2021). Antiviral Research.

https://doi.org/10.1016/j.antiviral.2021.105089

Source: Starpharma